Amgen shares slip as Novartis pelacarsen trial fails
Amgen shares dipped after Novartis’ Phase 3 pelacarsen failed to cut major CV events. Amgen also reported over $10B in quarterly sales driven by six product areas, with trial wins including IMDELLTRA and TEZSPIRE.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.